🔗 Share this article

Elected officials have issued warnings that the United Kingdom's negotiated accords with Donald Trump are "built on sand." This follows revelations that a so-called "milestone" deal on drug pricing, which commits to zero tariffs in exchange for the NHS increasing its costs, lacks any underlying contract beyond limited headline terms outlined by government press releases.

An Agreement in Principle Only

The arrangement concerning medicines, described as a "generational" achievement, remains an "broad understanding" without a signed legal text. It has been highlighted that the official announcements from the UK and US governments describe the deal in divergent terms. The British version focuses on securing "zero per cent tariffs" as a unique achievement, while the American announcement highlights the expectation for the NHS to pay significantly more for new medications.

"We face a genuine possibility that the UK government has agreed to terms to raise drug prices in return for only a pledge from President Trump," stated David Henig, a trade policy analyst. "We know he has form for not keeping promises."

A Pattern of Unreliability

Concerns have been intensified by Washington's action to suspend the major technology agreement, which was previously described as "a huge leap forward" in the bilateral relationship. The US claimed a insufficient movement from the UK on lowering trade barriers as the reason for the pause.

Additionally, concessions promised for British farmers as part of an May trade agreement have not been formally signed off by the US, despite a imminent January deadline. "We have been informed that that the US has not yet signed off the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

In confidential discussions, ministers have expressed concerns that the government's US-UK accords are unstable and unpredictable. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another described the situation as the "new normal" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, chair of the health select committee, argued: "What is even more astonishing than Trump's temper tantrums is the UK government's credulous faith that his administration is a trustworthy negotiator. The NHS is of vital importance."

Official Reassurances and Concrete Outcomes

Government figures have sought to reduce the risk of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, wanting clarity on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that volatility is a feature of dealing with the Trump administration. However, they argue that the UK has secured concrete outcomes for businesses, such as preferential tariff rates compared to other nations. "Securing 25% steel tariffs, which is better than the rate for the rest of the world, is a solid gain," one official said.

However, problems have surfaced in carrying out the broader trade deal. Promised access for British beef have not materialized, and the commitment to "remove tariffs on British steel and aluminium" has is still pending, with tariffs fixed at 25%.

Moving forward, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "productive" meetings between UK and US officials in Washington.